<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of osteomyelitis due to nontuberculous mycobacteria in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of osteomyelitis due to nontuberculous mycobacteria in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of osteomyelitis due to nontuberculous mycobacteria in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shannon Kasperbauer, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles L Daley, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kevin L Winthrop, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 18, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H542359567"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria (NTM) are a large group of organisms that are widespread in the environment  (<a class="graphic graphic_table graphicRef61936" href="/d/graphic/61936.html" rel="external">table 1</a>). They have been isolated from numerous environmental sources, including water and soil. NTM can cause a broad range of infections that vary depending on the NTM species and on the host's immune status. In immunocompetent individuals, disease can present as chronic pneumonia, lymphadenitis, or skin, soft tissue, and/or bone infection. Immunocompromised individuals can also present with any of these findings, but disease in such patients may also manifest as disseminated infection. Unfortunately, NTM are seldom considered as a possible etiology in infections of the soft tissues and/or bones; therefore, delays in diagnosis and treatment are common. </p><p>The treatment of osteomyelitis due to NTM will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of NTM osteomyelitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/85798.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria"</a>.)</p><p>Other NTM infections and the management of osteomyelitis due to bacteria and <em>Mycobacterium tuberculosis</em> are reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/5344.html" rel="external">"Epidemiology of nontuberculous mycobacterial infections"</a> and  <a class="medical medical_review" href="/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a> and  <a class="medical medical_review" href="/d/html/3705.html" rel="external">"Overview of nontuberculous mycobacteria (excluding MAC) in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/5341.html" rel="external">"Treatment of <i>Mycobacterium avium </i>complex pulmonary infection in adults"</a> and  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a> and  <a class="medical medical_review" href="/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7663.html" rel="external">"Vertebral osteomyelitis and discitis in adults"</a> and  <a class="medical medical_review" href="/d/html/7659.html" rel="external">"Osteomyelitis associated with open fractures in adults"</a> and  <a class="medical medical_review" href="/d/html/5958.html" rel="external">"Hematogenous osteomyelitis in children: Management"</a> and  <a class="medical medical_review" href="/d/html/7658.html" rel="external">"Bone and joint tuberculosis"</a>.)</p><p class="headingAnchor" id="H1649190421"><span class="h1">GENERAL PRINCIPLES</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of a multidisciplinary approach</strong> – Management of osteomyelitis caused by NTM includes combination antimycobacterial therapy, often with surgical debridement or excision. For patients on immunosuppressive agents, these should be minimized whenever possible. Collaboration between all medical and surgical providers is essential because of the difficult-to-treat nature of NTM. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Caveats to NTM isolation and susceptibility testing</strong> – Unlike isolation of <em>M. tuberculosis</em>, isolation of an NTM does not necessarily dictate initiation of therapy. Because NTM can be isolated as a result of contamination of a clinical specimen and because the pathogenicity of the various NTM species varies substantially, clinicians must determine the clinical significance of any isolate and whether treatment is indicated [<a href="#rid1">1</a>]. In addition, the results of in vitro antimicrobial susceptibility testing for many NTM do not correlate with clinical response, and therefore the clinician should use these data with an appreciation for the limitations of such testing. (See  <a class="medical medical_review" href="/d/html/85798.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of osteomyelitis due to nontuberculous mycobacteria", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limitations in supporting evidence</strong> – There are no randomized controlled trials or comparative observational studies that have evaluated the efficacy of treatment for NTM osteomyelitis. Thus, treatment recommendations are based upon case reports and small retrospective reviews, as well as on in vitro antimicrobial susceptibility results. Our recommendations for therapy are generally in keeping with the American Thoracic Society/Infectious Diseases Society of America guidelines on the management of NTM diseases [<a href="#rid1">1,2</a>], as well as our own clinical experience. </p><p></p><p class="bulletIndent1">These guidelines, as well as other society guidelines, can be found through the society guideline link below. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="headingAnchor" id="H1979020487"><span class="h1">ANTIMICROBIAL SUSCEPTIBILITY TESTING</span><span class="headingEndMark"> — </span>In vitro antimicrobial susceptibility testing is recommended for all clinically significant NTM isolated from the lesions of patients with osteomyelitis [<a href="#rid1">1</a>]. </p><p>Specific recommendations differ for each species, as detailed below. The Clinical and Laboratory Standards Institute recommends specific drugs and testing conditions for the most common species [<a href="#rid3">3,4</a>]. </p><p>For most NTM species, there is no known correlation between in vitro susceptibility results and the clinical response to therapy. In vitro susceptibility testing has not been validated for all NTM species. Despite these limitations, susceptibility testing plays an important role in the management of NTM osteomyelitis. Recommendations for susceptibility testing of each NTM species are discussed below. (See <a class="local">'Antimycobacterial therapy'</a> below.)</p><p>Susceptibility testing for NTM is also discussed separately. (See  <a class="medical medical_review" href="/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a>.)</p><p class="headingAnchor" id="H758105564"><span class="h1">ANTIMYCOBACTERIAL THERAPY</span><span class="headingEndMark"> — </span>The specific antimycobacterial regimen depends upon the NTM species isolated and, for certain species, on the results of in vitro antimicrobial susceptibility testing. It is important not to use monotherapy, which can lead to the development of resistance. </p><p>It is also crucial to design a regimen based on the specific NTM isolated, since there are differences in antimicrobial susceptibility among the species. Specific regimens for each NTM species are discussed below.</p><p class="headingAnchor" id="H542359581"><span class="h2">Rapidly growing mycobacteria</span><span class="headingEndMark"> — </span>Patients with osteomyelitis caused by rapidly growing mycobacterial species should receive combination antimycobacterial therapy, typically in conjunction with surgery. The rapidly growing mycobacteria tend to be more difficult to treat than slowly growing mycobacteria due to their inherent drug resistance. For this reason, surgical resection is critical for disease control and eradication. In rare cases, amputation is required for cure [<a href="#rid5">5,6</a>]. (See <a class="local">'Surgery'</a> below.)</p><p><em>Mycobacterium fortuitum</em>, <em>Mycobacterium chelonae</em>, and <em>Mycobacterium abscessus</em> (including the subspecies <em>M. abscessus</em>, <em>M. massiliense</em>, and <em>M. bolletii</em>) are resistant to antituberculosis agents (eg, <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>, and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>), but they are typically susceptible to various traditional antibacterial agents [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Most rapidly growing mycobacteria are susceptible in vitro to <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a>, carbapenems (<a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>), oxazolidinones (<a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a>), <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a>, and newer cycline derivatives (<a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>, <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a>) [<a href="#rid7">7-10</a>]. Imipenem is the most active carbapenem against rapidly growing mycobacteria [<a href="#rid9">9</a>]. Almost all rapidly growing mycobacteria are susceptible to tigecycline and other newer cycline derivatives. Omadacycline has excellent in vitro activity against rapidly growing mycobacteria, with minimum inhibitory concentration (MIC) 90 values of 0.25 mcg/mL, 0.5 mcg/mL, and 0.25 mcg/mL for <em>M. abscessus</em>, <em>M. chelonae</em>, and <em>M. fortuitum</em>, respectively [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Susceptibility to macrolides depends on the presence and activity of the <em>erm</em> gene, which confers inducible resistance to macrolides. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Detecting macrolide resistance'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Susceptibility to fluoroquinolones (<a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>), <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, and <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>/sulfamethoxazole is variable [<a href="#rid7">7-10</a>]. Most strains of <em>M. fortuitum</em> and <em>M. chelonae</em> are susceptible to moxifloxacin, but <em>M. abscessus</em> is almost universally resistant [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Susceptibility to aminoglycosides varies between species. <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">Amikacin</a> is generally the most active aminoglycoside; the exception is <em>M. chelonae</em>, against which <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> is more active. </p><p></p><p>In vitro antimicrobial susceptibility testing should be performed on all clinically significant isolates of rapidly growing mycobacteria (eg, <em>M. fortuitum</em> complex, <em>M. chelonae</em>, <em>M. abscessus</em>), including isolates that have been recovered after treatment failure or relapse [<a href="#rid1">1,3,4</a>]. The Clinical and Laboratory Standards Institute recommends that the following antimicrobial drugs be tested for in vitro susceptibility: <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>/sulfamethoxazole, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, and <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a>. Moxifloxacin susceptibility testing is necessary even when ciprofloxacin is tested, since ciprofloxacin susceptibility cannot be extrapolated to moxifloxacin. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Susceptibility testing'</a>.)</p><p class="headingAnchor" id="H542359588"><span class="h3">M. fortuitum complex</span><span class="headingEndMark"> — </span><em>M. fortuitum</em> complex includes at least 12 species, of which <em>M. fortuitum</em> is the most common [<a href="#rid12">12</a>]. For initial therapy, we suggest a combination of ≥3 agents, including one to two oral agents and one to two parenteral agents to which the isolate is susceptible, adjusted for renal dysfunction [<a href="#rid1">1</a>]. The final number of antimicrobial agents used in the regimen will depend on the in vitro susceptibility pattern, which drugs are available, the site, and the extent of disease. It is important to note that monotherapy is not considered appropriate, given the risk of inducing resistance. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">Amikacin</a> 15 mg/kg intravenously (IV) once daily or 15 to 25 mg/kg IV three times weekly</p><p></p><p class="bulletIndent1"><strong>PLUS </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One of the following IV agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">Imipenem</a> 750 to 1000 mg IV every 12 hours</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">Cefoxitin</a> 3 g IV every 8 to 12 hours</p><p></p><p class="bulletIndent1"><strong>PLUS </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One to two of the following oral agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg once daily (or <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 to 750 mg twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg twice daily (or <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a> 300 mg daily) </p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">Clofazimine</a> 100 mg daily (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04334070&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRmWQ1VdqegPkaQxuuEOThGurkacawmSXMpQGwOQ1EIXQ%3D%3D&amp;TOPIC_ID=13995" target="_blank">can be obtained</a> through an expanded-access program or single-patient investigational new drug application)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> 600 mg daily (or <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a> 200 mg daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> (3.5 to 4 mg/kg of the <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a> component every 8 to 12 hours) </p><p></p><p>These doses are for patients with normal renal function. </p><p>The duration of parenteral therapy is not well defined. We suggest continuing this initial parenteral combination regimen for six to eight weeks and then switching to an oral regimen that includes at least two agents to which the isolate is susceptible in vitro. Total duration of antimycobacterial therapy is discussed elsewhere. (See <a class="local">'Duration of therapy'</a> below.)</p><p>Oral agents that typically have in vitro activity against <em>M. fortuitum</em> complex include <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>/sulfamethoxazole, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> and <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, and <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> and <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a> [<a href="#rid12">12</a>]. However, most <em>M. fortuitum, Mycobacterium porcinum, and Mycobacterium septicum</em> isolates<em> </em>carry an inducible <a class="drug drug_general" data-topicid="9418" href="/d/drug information/9418.html" rel="external">erythromycin</a> methylase gene, <em>erm</em>(39), which confers inducible macrolide resistance; macrolides should be avoided if the <em>erm</em> gene is present [<a href="#rid12">12,13</a>]. In contrast, approximately two-thirds of <em>Mycobacterium peregrinum</em> isolates are susceptible to macrolides. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Detecting macrolide resistance'</a>.)</p><p>IV agents with in vitro activity include <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, and <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> [<a href="#rid1">1,14-17</a>]. Imipenem is the preferred carbapenem, although <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> may also be used; <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a> and doripenem have limited activity. Many isolates are susceptible to cycline derivatives (<a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a>, <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>, tigecycline) and <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a>. </p><p>No randomized trials or comparative observational studies have been performed to inform treatment outcomes. In one study that included 76 patients with extrapulmonary infections due to <em>M. fortuitum</em>, 68 patients (90 percent) were successfully treated with antimycobacterial therapy with or without surgery [<a href="#rid18">18</a>]. Most patients had skin and soft tissue infections, but 15 had osteomyelitis. The majority of patients with extensive disease underwent surgical debridement in combination with antimycobacterial therapy. Patients received a variety of regimens, ranging from combination parenteral therapy with <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> plus <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a> to oral monotherapy with a sulfonamide, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, or amikacin. However, for osteomyelitis, we do not recommend monotherapy. The mean duration of antimycobacterial therapy for patients with osteomyelitis was seven months. </p><p class="headingAnchor" id="H542359595"><span class="h3">M. chelonae</span><span class="headingEndMark"> — </span>Treatment of <em>M. chelonae</em> disease is difficult due to multidrug resistance and the dearth of oral antibiotics for therapy. </p><p>For initial therapy, we suggest a combination of ≥3 agents, including a macrolide (preferably <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), another one to two oral agents, and one to two parenteral agents to which the isolate is susceptible [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>One to two of the following IV agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">Tobramycin</a> 4 to 7 mg/kg IV once daily or three times weekly</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">Imipenem</a> 750 to 1000 mg IV every 12 hours</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">Tigecycline</a> 50 mg IV once daily (or every 12 hours if tolerated)</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg once daily (or <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> 500 mg twice daily)</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>One to two of the following oral agents:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">Moxifloxacin</a> 400 mg once daily (or <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 to 750 mg twice daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg twice daily (or <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a> 300 mg daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">Clofazimine</a> 100 mg daily (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04334070&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRmWQ1VdqegPkaQxuuEOThGurkacawmSXMpQGwOQ1EIXQ%3D%3D&amp;TOPIC_ID=13995" target="_blank">can be obtained</a> through an expanded-access program or single-patient investigational new drug application)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> 600 mg daily (or <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a> 200 mg daily)</p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> 3.5 to 4 mg/kg of the <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a> component every 8 to 12 hours </p><p></p><p>These doses are for patients with normal renal function. </p><p>The duration of parenteral therapy is not well defined. We usually continue the initial parenteral combination regimen for 8 to 12 weeks until there are signs of clinical improvement, and we then switch to an oral regimen that includes two to three agents to which the isolate is susceptible. Total duration of antimycobacterial therapy is discussed elsewhere. (See <a class="local">'Duration of therapy'</a> below.)</p><p>The macrolides <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a> and <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a> are the only oral agents to which <em>M. chelonae</em> is typically susceptible [<a href="#rid1">1,11,16,19,20</a>]. Up to 20 percent of <em>M. chelonae</em> isolates from one case series were susceptible to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and sulfamethoxazole [<a href="#rid19">19</a>]. Although prior evidence suggested reasonable susceptibility to fluoroquinolones and <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, in a subsequent in vitro assessment of 526 strains of <em>M. chelonae</em>, most strains were resistant to these agents [<a href="#rid21">21</a>].</p><p>Based on in vitro susceptibility patterns, the most promising parenteral agents are <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> [<a href="#rid15">15</a>], <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> [<a href="#rid17">17</a>], <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a> [<a href="#rid11">11,22</a>], and <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a> [<a href="#rid11">11</a>]. Tobramycin has greater activity against <em>M. chelonae</em> than <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, in contrast to other rapidly growing mycobacteria [<a href="#rid15">15</a>]. <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">Cefoxitin</a> typically does <strong>not</strong> have activity against <em>M. chelonae</em> [<a href="#rid1">1</a>]. </p><p>In an observational study that included 47 patients with nonpulmonary infections due to <em>M. chelonae</em> or <em>M. abscessus</em>, 34 patients (72 percent) were successfully treated [<a href="#rid18">18</a>]. The outcomes for these two species were combined, so it is not possible to determine the outcomes of those infected with <em>M. chelonae </em>alone. Only seven patients had osteomyelitis.</p><p class="headingAnchor" id="H542359602"><span class="h3">M. abscessus</span><span class="headingEndMark"> — </span><em>M. abscessus</em> (and its subspecies, <em>M. abscessus</em>, <em>M. massiliense</em>, and <em>M. bolletii</em> [<a href="#rid23">23-26</a>]) is challenging to treat because it is resistant to many agents that are used to treat other NTM infections [<a href="#rid1">1</a>]. We suggest a combined medical and surgical approach for treatment of <em>M. abscessus</em> osteomyelitis. We also recommend subspecies identification and in vitro susceptibility testing, including assessment for inducible macrolide resistance in <strong>all</strong> clinically significant isolates. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Nomenclature for M. abscessus'</a>.)</p><p class="headingAnchor" id="H2757627825"><span class="h4">Regimen selection</span><span class="headingEndMark"> — </span>Regimen selection depends on the presence or activity of the <em>erm</em> gene, which confers inducible macrolide resistance despite in vitro susceptibility at three to five days. The majority of subspecies <em>M. abscessus</em> and <em>M. bolletii</em> contain an <em>erm</em>(41) gene. However, there are some <em>M. abscessus</em> isolates that have a T-to-C polymorphism at nucleotide 28 of the <em>erm</em>(41) gene, which inactivates the gene, and these isolates are susceptible to macrolides [<a href="#rid27">27</a>]. Similarly, the <em>erm</em>(41) gene in <em>M. massiliense</em> is nonfunctional due to truncation, so inducible resistance does not occur [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Detecting macrolide resistance'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>M. massiliense</em></strong><strong> or</strong> <strong><em>M. abscessus </em></strong><strong>with a nonfunctional</strong><strong><em> erm </em></strong><strong>gene (C28 sequevar)</strong> – For initial therapy of these subspecies, we suggest a combination of at least 3 agents, including at least two oral agents (including a macrolide) and one to two parenteral agents to which the isolate is susceptible. All of the following doses are for patients with normal renal function. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">Amikacin</a> 10 to 15 mg/kg IV once daily or 15 to 25 mg/kg IV three times weekly </p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One of the following IV agents:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">Imipenem</a> 750 to 1000 mg IV every 12 hours (preferred)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">Cefoxitin</a> 3 g IV every 8 to 12 hours</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">Tigecycline</a> 50 mg IV once daily or every 12 hours </p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">Omadacycline</a> IV 100 mg once daily</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">Eravacycline</a> 1 mg/kg IV every 12 hours </p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg once daily (or <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> 500 mg twice daily)</p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one of the following oral agents:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">Clofazimine</a> 100 mg once daily<strong> </strong>(<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04334070&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRmWQ1VdqegPkaQxuuEOThGurkacawmSXMpQGwOQ1EIXQ%3D%3D&amp;TOPIC_ID=13995" target="_blank">can be obtained</a> through an expanded-access program or single-patient investigational new drug application)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">Omadacycline</a> 300 mg once daily (if not receiving an IV <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> 600 mg once daily (or <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a> 200 mg once daily) </p><p></p><p class="bulletIndent1">The duration of parenteral therapy is not well defined. We suggest continuing one of the regimens outlined above for at least 8 to 12 weeks and then switching to an oral regimen. Factors that influence the duration of parenteral therapy include extent of disease, host immunosuppression, susceptibility of the organism, and whether surgical debridement is performed. Total duration of antimycobacterial therapy is discussed elsewhere. (See <a class="local">'Duration of therapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong><em>M. abscessus </em></strong><strong>with a functional </strong><strong><em>erm</em></strong><strong> gene (T28 sequevar) or </strong><strong><em>M. bolletii</em></strong><em> </em>–<strong> </strong>For initial therapy of these subspecies, we suggest a combination of at least four agents (not including a macrolide), including two parenteral agents to which the isolate is susceptible. All of the following doses are for patients with normal renal function. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">Amikacin</a> 10 to 15 mg/kg IV once daily or 25 mg/kg IV three times weekly </p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>At least one of the following IV agents:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">Imipenem</a> 750 to 1000 mg IV every 12 hours (preferred)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">Cefoxitin</a> 3 g IV every 8 to 12 hours</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">Tigecycline</a> 50 mg IV once daily or every 12 hours</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">Omadacycline</a> IV 100 mg once daily</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">Eravacycline</a> 1 mg/kg IV every 12 hours </p><p></p><p class="bulletIndent2"><strong>PLUS</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Two of the following oral agents:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">Clofazimine</a> 100 mg once daily<strong> </strong>(<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04334070&amp;token=nbsXe3i4qfUea5RCPRHtOY5G%2FPzFIESeuM6wIJ4nJiRmWQ1VdqegPkaQxuuEOThGurkacawmSXMpQGwOQ1EIXQ%3D%3D&amp;TOPIC_ID=13995" target="_blank">can be obtained</a> through an expanded-access program or single-patient investigational new drug application)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">Omadacycline</a> 300 mg once daily (if not receiving an IV <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> derivative) </p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> 600 mg once daily (or <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a> 200 mg once daily)</p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">Bedaquiline</a> 400 mg daily for two weeks, then 200 mg three times a week </p><p></p><p class="bulletIndent1">The duration of parenteral therapy is not well defined. We suggest continuing one of the regimens outlined above for at least 12 weeks and then switching to an oral regimen if possible. Some patients will need to continue parenteral therapy throughout the course of treatment if the isolate does not have at least two companion oral agents with in vitro activity. Total duration of antimycobacterial therapy is discussed elsewhere. (See <a class="local">'Duration of therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H1290006753"><span class="h4">In vitro activity and efficacy of options</span><span class="headingEndMark"> — </span>Parenteral agents that typically have in vitro activity against <em>M. abscessus</em> include <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a>, <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a>, <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a>, and <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a>. Imipenem is the preferred carbapenem, although meropenem may also be used; <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a> and doripenem have limited activity [<a href="#rid9">9</a>]. We prefer imipenem to cefoxitin, as it has been shown to be superior to cefoxitin in time-kill and macrophage assays and is better tolerated [<a href="#rid29">29</a>]. We also prefer imipenem to tigecycline, as the optimal dose for tigecycline in a hollow-fiber model was 200 mg per day, which would be toxic to patients [<a href="#rid30">30</a>]. In fact, most patients require a reduced dose of 25 to 50 mg per day in order to tolerate the medication [<a href="#rid31">31,32</a>]. If we use tigecycline, we typically start with 50 mg IV every 12 hours but often have to reduce the dose to once daily in patients who have substantial nausea and vomiting. Pretreatment with antiemetic therapy can be used to facilitate twice-daily dosing, but it may not be adequate in many patients [<a href="#rid32">32</a>]. </p><p>The only oral agent with reliable activity against subspecies <em>M. abscessus</em> is <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a> [<a href="#rid33">33-36</a>]. Other oral agents with possible activity include macrolides (<a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>), fluoroquinolones (<a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>), oxazolidinones (<a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a>), <a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">bedaquiline</a>, and <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a>. One study of <em>M. abscessus</em> isolates noted that clarithromycin induces greater <em>erm</em>(41) expression and thus higher macrolide resistance than azithromycin [<a href="#rid37">37</a>]. Therefore, azithromycin may be more effective in <em>M. abscessus</em> infections. </p><p><a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">Bedaquiline</a> is an oral diarylquinoline with activity against <em>M. tuberculosis</em>. The MIC90 against <em>M. abscessus</em> has been reported to be 0.125 mcg/mL [<a href="#rid10">10,12</a>]; however, the drug is bacteriostatic. In a mouse model evaluating bedaquiline with other compounds, use with <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a> showed improved activity against <em>M. abscessus</em> [<a href="#rid38">38</a>], but there are cardiovascular safety and dual cross-resistance concerns with the combination. Clinical data on bedaquiline for <em>M. abscessus</em> are limited [<a href="#rid39">39</a>]. </p><p><a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">Tedizolid</a> is an oxazolidinone with MICs 4- to 16-fold lower than those of <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> against <em>M. abscessus</em> [<a href="#rid40">40,41</a>]. Like linezolid, it is bacteriostatic with some increased activity when given with <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> and <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> in vitro [<a href="#rid41">41-44</a>]. There are no clinical case series describing its effectiveness. </p><p><a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">Omadacycline</a> is a novel aminomethylcycline that comes in both oral and IV formulations. Limited clinical data have described omadacycline use in extrapulmonary <em>M. abscessus</em> infections [<a href="#rid45">45,46</a>]. In vitro data have demonstrated activity similar to <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> but with better tolerance and pharmacokinetic parameters [<a href="#rid47">47-51</a>]. </p><p><em>M. abscessus</em> has a beta-lactamase called Bla<sub>Mab</sub>, which efficiently hydrolyzes beta-lactams [<a href="#rid52">52</a>]. Adding clavulanate, sulbactam, or tazobactam to beta-lactams does not improve activity, but adding avibactam, relebactam, or vaborbactam can increase activity of some beta-lactam antibiotics [<a href="#rid53">53</a>]. For example, addition of avibactam significantly improves in vitro activity of <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a> but not <a class="drug drug_general" data-topicid="8553" href="/d/drug information/8553.html" rel="external">imipenem</a> or <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a> [<a href="#rid54">54</a>]. Furthermore, combinations of carbapenems and other beta-lactams such as ceftaroline or <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a> result in significant decreases in MICs against <em>M. abscessus</em> [<a href="#rid55">55</a>]. Dual beta-lactam agents with or without beta-lactamase inhibitors are beginning to be used clinically, but there are no clinical series or trials yet available. </p><p>The evidence for efficacy of treatment regimens for <em>M. abscessus</em> comes primarily from retrospective studies of <em>M. abscessus</em> pulmonary infections [<a href="#rid56">56,57</a>]. One study of nonpulmonary infections caused by rapidly growing mycobacteria included 47 cases of <em>M. chelonae</em>, 32 of which were further classified as being <em>M. chelonae</em> subspecies <em>abscessus</em> (now called<em> M. abscessus</em>) [<a href="#rid18">18</a>]. The overall success rate for infections caused by <em>M. abscessus</em> or <em>M. chelonae</em> was 72 percent, but the major cause of treatment failure was the absence of an oral drug with activity against <em>M. abscessus</em>. Another study of 20 extrapulmonary infections caused by subspecies <em>M. abscessus</em> and <em>M. massiliense</em> included six patients with bone and joint disease, all of whom received IV and oral therapy for a median of 23 and 343 days, respectively, in addition to surgery [<a href="#rid58">58</a>]. Treatment success rates were higher in patients infected with either <em>M. massiliense</em> or <em>M. abscessus</em> with a nonfunctional <em>erm</em> gene (the C28 sequevar) than in those infected with <em>M. abscessus</em> with a functional <em>erm</em> gene (the T28 sequevar).</p><p class="headingAnchor" id="H542359616"><span class="h2">Slowly growing mycobacteria</span></p><p class="headingAnchor" id="H542359623"><span class="h3">M. avium complex</span><span class="headingEndMark"> — </span>For patients with localized osteomyelitis due to <em>Mycobacterium avium</em> complex (MAC), we suggest a combination of excisional surgery or surgical debridement and antimycobacterial therapy [<a href="#rid1">1</a>]. For MAC isolates, antimicrobial susceptibility testing should be performed for <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> [<a href="#rid3">3,4</a>]. (See <a class="local">'Surgery'</a> below.)</p><p>We suggest that patients receive the following regimen, adjusted for renal dysfunction [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg once daily <strong>or</strong> <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> 500 mg twice daily.</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg orally daily. </p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> 10 mg/kg once daily (maximum daily dose 600 mg); in patients with human immunodeficiency virus (HIV) receiving antiretroviral therapy with an agent that has strong interactions with rifampin, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> 150 to 300 mg once daily can be used. (See  <a class="medical medical_review" href="/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Drug interactions'</a>.)</p><p></p><p>IV <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> or intramuscular <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a> (each dosed at 10 to 15 mg/kg daily or 15 to 25 mg/kg three times weekly) should be added for severe or disseminated infection or in patients who respond poorly to the regimen outlined above. When amikacin or streptomycin is used, it is typically continued for the first two or three months. Total duration of antimycobacterial therapy is discussed elsewhere. (See <a class="local">'Duration of therapy'</a> below.)</p><p>Immunocompromised patients generally require a more complex regimen to treat disseminated disease. Immunocompromised patients also require a longer duration of therapy. These issues are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/3755.html" rel="external">"Mycobacterium avium complex (MAC) infections in persons with HIV"</a> and  <a class="medical medical_review" href="/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients", section on 'Treatment'</a>.)</p><p>As above, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> and <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> susceptibility testing should be performed for new (previously untreated) isolates; clarithromycin susceptibility should also be tested in isolates from patients who have not responded to macrolide therapy after several months. Since clarithromycin and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> share cross-resistance and susceptibility, the results of clarithromycin susceptibility testing can be extrapolated to azithromycin [<a href="#rid1">1,3,4</a>]. In patients who fail initial macrolide-based therapy, we also suggest testing susceptibility to <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, and <a class="drug drug_general" data-topicid="107872" href="/d/drug information/107872.html" rel="external">clofazimine</a>. Susceptibility testing should also be considered for <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> and <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>.</p><p><a class="drug drug_general" data-topicid="87509" href="/d/drug information/87509.html" rel="external">Bedaquiline</a> has even better activity against MAC than <em>M. abscessus</em>, but there remains a very limited amount of clinical data regarding its efficacy in the treatment of patients with MAC disease [<a href="#rid12">12,39</a>].</p><p class="headingAnchor" id="H542359630"><span class="h3">M. kansasii</span><span class="headingEndMark"> — </span>In patients with <em>Mycobacterium kansasii</em> osteomyelitis, antimycobacterial therapy with a combined regimen similar to a regimen used for tuberculosis (<a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>) has been successful even without surgical debridement [<a href="#rid59">59-62</a>]. <em>M. kansasii</em> is highly susceptible to macrolides, and treatments with macrolide-based regimens that include rifampin and ethambutol have been shown to be effective in patients with pulmonary disease [<a href="#rid63">63,64</a>]. For the initial treatment of <em>M. kansasii</em>, antimicrobial susceptibility testing should be performed for rifampin and <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> [<a href="#rid3">3,4</a>]. </p><p>We suggest the following oral combination regimen for patients with <em>M. kansasii</em> osteomyelitis, adjusted for renal dysfunction [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg once daily <strong>or</strong> <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> 500 mg twice daily</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> 10 mg/kg once daily (maximum daily dose 600 mg) </p><p></p><p class="bulletIndent1"><strong>PLUS </strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg per day </p><p></p><p>We recommend continuing antimycobacterial therapy for at least six months.</p><p>Rifamycins play a critically important role in the treatment of <em>M. kansasii</em> disease; therefore, it is important to use a rifamycin-based regimen even in the setting of concomitant antiretroviral therapy for HIV infection, despite the drug-drug interactions [<a href="#rid1">1</a>]. This recommendation is based upon the observation that substantial rates of relapse occurred in the pre-rifampin era and that outcomes improved dramatically after the introduction of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for the treatment of pulmonary <em>M. kansasii</em> infections [<a href="#rid1">1,65-68</a>]. The use of rifamycins in patients receiving antiretroviral therapy is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Drug interactions'</a>.)</p><p>Isolates that demonstrate in vitro susceptibility to <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> are also susceptible to <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>. Although <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> are used in the treatment of <em>M. kansasii</em>, MIC values correlate poorly with clinical response, and testing is not recommended [<a href="#rid3">3,4</a>]. If the isolate is rifampin resistant, susceptibility testing to the following agents is recommended: <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, rifabutin, and <a class="drug drug_general" data-topicid="10024" href="/d/drug information/10024.html" rel="external">trimethoprim</a>/sulfamethoxazole. Moxifloxacin susceptibility testing is necessary even when ciprofloxacin is tested, since ciprofloxacin susceptibility cannot be extrapolated to moxifloxacin. Because of its excellent in vitro activity against <em>M. kansasii</em>, moxifloxacin is a potential substitute for rifampin in resistant or intolerant cases.</p><p class="headingAnchor" id="H542359637"><span class="h3">M. haemophilum</span><span class="headingEndMark"> — </span>Based on reported cases, combinations of antibiotics, including <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, and a rifamycin, appear to be effective in the treatment of osteomyelitis caused by <em>Mycobacterium haemophilum</em> [<a href="#rid1">1,69,70</a>]. In addition to these agents, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> also appears to have in vitro activity against <em>M. haemophilum</em> [<a href="#rid1">1,70,71</a>]. In contrast, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> and sulfonamides have variable activity against <em>M. haemophilum</em>, and all clinical isolates are resistant to <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> [<a href="#rid72">72</a>]. There are no standardized in vitro susceptibility methods for <em>M. haemophilum</em>; therefore, when in vitro antimicrobial susceptibility testing is performed, the results must be interpreted with caution [<a href="#rid1">1</a>].</p><p>For the treatment of <em>M. haemophilum</em>, we suggest the following oral combination regimen, adjusted for renal dysfunction [<a href="#rid69">69,70</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg once daily <strong>or</strong> <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> 500 mg twice daily</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">Ciprofloxacin</a> 500 mg twice daily <strong>or</strong> <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg daily </p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> 10 mg/kg once daily (maximum daily dose 600 mg) <strong>or</strong> <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a> 150 to 300 mg daily</p><p></p><p>In patients with extensive or severe disease, we add <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a> 15 mg/kg IV once daily or 15 to 25 mg/kg three times weekly to the oral regimen described above. We continue the amikacin for at least 12 weeks, but we continue the three oral agents for a longer period. Therapy should continue for at least 6 months and for up to 24 months depending on the clinical response [<a href="#rid70">70</a>]. </p><p>Surgery is performed in selected cases. (See <a class="local">'Surgery'</a> below.)</p><p class="headingAnchor" id="H542359644"><span class="h3">M. marinum</span><span class="headingEndMark"> — </span><em>Mycobacterium marinum</em> isolates are usually susceptible in vitro to macrolides, rifamycins, <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a>, and sulfonamides; susceptible or intermediately susceptible to <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, and <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>; and resistant to <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> [<a href="#rid1">1,73</a>]. Antimicrobial susceptibility testing is not routinely recommended for <em>M. marinum</em>, but it should be performed in patients who do not respond to therapy after three months [<a href="#rid1">1,3,4</a>]. When testing is performed, we suggest testing <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9863" href="/d/drug information/9863.html" rel="external">rifabutin</a>, ethambutol, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>, a sulfonamide, doxycycline, minocycline, <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, and streptomycin. </p><p>For the treatment of osteomyelitis due to <em>M. marinum</em>, we suggest the following oral regimen, adjusted for renal dysfunction [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> 250 to 500 mg once daily or <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a> 500 mg twice daily</p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">Ethambutol</a> 15 mg/kg per day </p><p></p><p class="bulletIndent1"><strong>PLUS</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> 10 mg/kg once daily (maximum daily dose 600 mg)</p><p></p><p>We recommend continuing antimycobacterial therapy for at least six months. </p><p>The 2007 American Thoracic Society/Infectious Diseases Society of America guidelines recommended a regimen that includes at least two medications and noted that a macrolide and <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> may represent the best balance between efficacy and tolerability [<a href="#rid1">1</a>]. Although milder forms of cutaneous disease have sometimes been treated successfully with monotherapy, we do not recommend this approach for osteomyelitis. Most patients who have been treated successfully with more invasive infections, including osteomyelitis, received two to three drugs. </p><p>Surgery is performed in selected cases. In a study that included 63 patients with <em>M. marinum </em>infection, approximately half of the patients underwent surgery, and failure of therapy was related to deep structural involvement [<a href="#rid73">73</a>]. In another study that included 10 patients with osteomyelitis due to <em>M. marinum</em>, six recovered and three underwent amputation [<a href="#rid74">74</a>]. (See <a class="local">'Surgery'</a> below.) </p><p><em>M. marinum</em> soft tissue infections are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7646.html" rel="external">"Soft tissue infections following water exposure"</a>.)</p><p class="headingAnchor" id="H542359651"><span class="h3">M. ulcerans</span><span class="headingEndMark"> — </span>The standard of care for Buruli ulcer, which is caused by <em>Mycobacterium ulcerans</em>, has been antimycobacterial therapy in combination with surgical debridement and skin grafting, when necessary. The treatment of Buruli ulcer is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5349.html" rel="external">"Buruli ulcer (Mycobacterium ulcerans infection)"</a>.)</p><p class="headingAnchor" id="H51756785"><span class="h3">Other species</span><span class="headingEndMark"> — </span>Other slowly growing mycobacterial species that have been reported rarely to cause osteomyelitis include <em>M. scrofulaceum</em>, <em>M. simiae</em>, <em>M. szulgai</em>, <em>M. terrae</em> complex, and <em>M. xenopi</em>. The general approach to therapy is similar to the approach to the other slowly growing mycobacterial species. We suggest consultation with an infectious diseases specialist with experience treating infections with these organisms.</p><p class="headingAnchor" id="H14965826"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of antimycobacterial therapy depends upon several factors, including the extent of disease, response to treatment, the causative species, the immune status of the patient, and whether surgical debridement was performed. For most NTM species, antimycobacterial therapy should be continued for a minimum of six months and is sometimes given for 12 months or longer [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H14974796"><span class="h2">Monitoring during therapy</span><span class="headingEndMark"> — </span>Monitoring for adverse effects of antimycobacterial therapy is important given the potential toxicities of the agents used. Patients should be monitored for evidence of hepatotoxicity (<a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>, rifamycins, macrolides, oxazolidinones); nephrotoxicity (<a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a>, <a class="drug drug_general" data-topicid="8536" href="/d/drug information/8536.html" rel="external">amikacin</a>, <a class="drug drug_general" data-topicid="10238" href="/d/drug information/10238.html" rel="external">streptomycin</a>); auditory and vestibular function (tobramycin, amikacin, streptomycin, macrolides); and hematologic toxicity (rifamycins, sulfonamides, <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a>, oxazolidinones). We check a complete blood count and a comprehensive metabolic panel (including liver function tests) weekly when on IV therapy and monthly thereafter on oral therapy.</p><p>For aminoglycosides, monitoring should include routine questioning about balance, ability to walk (especially in the dark), tinnitus, ear fullness, dizziness, and difficulty hearing. Baseline blood urea nitrogen and creatinine measurements should be obtained. Periodic monitoring of renal function is recommended for high-risk patients receiving an aminoglycoside, especially in patients older than 50 years or who have impairment of renal function. A baseline hearing test should be performed and then repeated monthly or sooner if signs or symptoms of eighth nerve toxicity appear. (See  <a class="medical medical_review" href="/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum", section on 'Monitoring for drug toxicity'</a>.)</p><p>Repeat imaging should be performed with any recurrence of symptoms or lapse from treatment. Repeat imaging at the end of therapy is helpful to establish a new baseline. In addition, we typically repeat imaging six months after the completion of therapy to evaluate for possible relapse.</p><p>We monitor serum inflammatory markers (erythrocyte sedimentation rate, C-reactive protein) when the diagnosis of osteomyelitis is first established and monthly during therapy.</p><p class="headingAnchor" id="H14973260"><span class="h2">Adverse effects</span><span class="headingEndMark"> — </span>The antimycobacterial agents that are used to treat NTM osteomyelitis are often difficult to tolerate, and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with aminoglycosides, optic neuropathy with <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> and <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, and hepatotoxicity with <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a>. The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7242.html" rel="external">"Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"</a> and  <a class="medical medical_review" href="/d/html/7214.html" rel="external">"Manifestations of and risk factors for aminoglycoside nephrotoxicity"</a> and  <a class="medical medical_review" href="/d/html/478.html" rel="external">"Ethambutol: An overview"</a> and  <a class="medical medical_review" href="/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'Adverse reactions'</a> and  <a class="medical medical_review" href="/d/html/491.html" rel="external">"Rifamycins (rifampin, rifabutin, rifapentine)"</a> and  <a class="medical medical_review" href="/d/html/481.html" rel="external">"Isoniazid: An overview"</a> and  <a class="medical medical_review" href="/d/html/477.html" rel="external">"Isoniazid hepatotoxicity"</a> and  <a class="medical medical_review" href="/d/html/483.html" rel="external">"Aminoglycosides", section on 'Toxicity'</a>.)</p><p class="headingAnchor" id="H14973535"><span class="h2">Drug interactions</span><span class="headingEndMark"> — </span>Immunocompromised patients, such as solid organ transplant recipients, are often receiving immunosuppressive agents, such as calcineurin inhibitors that interact with certain antimycobacterial agents (eg, <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, <a class="drug drug_general" data-topicid="9273" href="/d/drug information/9273.html" rel="external">clarithromycin</a>). These interactions are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1413.html" rel="external">"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients", section on 'Treatment'</a>.)</p><p>Certain antiretroviral agents for HIV infection also have important interactions with the rifamycins, especially <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>. (See  <a class="medical medical_review" href="/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Drug interactions'</a>.)</p><p>Specific interactions between medications may be determined using the <a class="external" href="/drug-interactions">drug interactions program</a>. This program can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions.</p><p class="headingAnchor" id="H115152665"><span class="h1">SURGERY</span><span class="headingEndMark"> — </span>Surgery plays an important role in the treatment of NTM osteomyelitis, particularly since the rate of side effects and drug interactions from antimycobacterial therapy is high and may limit the tolerance to medical therapy alone. In addition, some NTM respond poorly to antimycobacterial therapy. In our experience, more aggressive surgical intervention early in the course of the disease can often decrease the number of surgeries needed and shorten the overall course of therapy. (See <a class="local">'Duration of therapy'</a> above.) </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with localized osteomyelitis due to <em>M. avium</em> complex (MAC), we suggest a combination of excisional surgery or surgical debridement and antimycobacterial therapy [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also suggest aggressive surgical intervention for osteomyelitis due to other NTM species when there is extensive local involvement, when an abscess is present, or when antimycobacterial therapy alone is poorly tolerated or does not result in clinical improvement. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We recommend early surgical intervention for NTM species that are difficult to treat medically, such as <em>M. chelonae</em>, <em>M. abscessus</em>, and <em>M. haemophilum</em>. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A combined medical and surgical approach is also recommended for patients with vertebral osteomyelitis in order to minimize the risk of neurologic sequelae [<a href="#rid75">75</a>]. In a review of 69 patients with NTM vertebral osteomyelitis, approximately 70 percent underwent surgery in addition to antimicrobial therapy [<a href="#rid17">17,76</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgery should also be performed when the closed spaces of the hand are involved; this is most likely to occur with <em>M. marinum</em> infection, since infection with this species is usually acquired through handling the contents of aquatic environments.</p><p></p><p>High-quality evidence demonstrating the efficacy of surgical debridement for NTM osteomyelitis is lacking, and no guidelines exist regarding which patients should undergo surgery in addition to medical therapy. In a report of 22 patients with NTM otomastoiditis treated with antibiotics for a median of five months, 20 (18 of which were due to <em>M. abscessus</em>) underwent surgery, and 4 required revision surgery [<a href="#rid77">77</a>]. No recurrence was noted after a median follow-up of 12 months.</p><p>Several reports have described the use of bone cement [<a href="#rid78">78-82</a>], beads [<a href="#rid83">83-85</a>], and spacers [<a href="#rid86">86,87</a>] impregnated with antibiotics [<a href="#rid88">88</a>] in the setting of osteomyelitis. However, few reports have described these procedures in patients with mycobacterial infections [<a href="#rid82">82,89-91</a>]. Systemic toxicity has been reported with antibiotic-laden bone cement [<a href="#rid92">92,93</a>]. As an example, two cases of acute kidney injury were associated with the use of tobramycin-laden cement incorporated in total hip arthroplasties, and both patients had elevated serum <a class="drug drug_general" data-topicid="10000" href="/d/drug information/10000.html" rel="external">tobramycin</a> concentrations [<a href="#rid93">93</a>]. When aminoglycoside-laden cement is used, serum aminoglycoside concentrations should be monitored. (See  <a class="medical medical_review" href="/d/html/483.html" rel="external">"Aminoglycosides", section on 'Toxicity'</a>.)</p><p class="headingAnchor" id="H1979020388"><span class="h1">MANAGING POOR TREATMENT RESPONSES</span><span class="headingEndMark"> — </span>Most patients will respond to therapy with improvements in symptoms and serum inflammatory markers (C-reactive protein, erythrocyte sedimentation rate) within the first month of therapy. Improvement in imaging studies will take longer, often months after treatment initiation. If the patient does not respond to antimycobacterial therapy, we suggest surgical debridement, repeating cultures and performing (or repeating) in vitro susceptibility testing, and additional antimycobacterial therapy, such as the addition of a parenteral agent.</p><p class="headingAnchor" id="H1979019417"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Given the rarity of NTM osteomyelitis and the sparsity of studies, the outcomes of NTM osteomyelitis have not been clearly defined. In our experience, most patients with osteomyelitis due to NTM can be cured with appropriate surgical debridement and antimicrobial therapy. (See <a class="local">'Antimycobacterial therapy'</a> above and <a class="local">'Surgery'</a> above.)</p><p>Outcomes depend on several factors, including the immune status of the host, the extent and location of the infection, and the causative species. </p><p>As an example of the differences in outcome based upon the causative species, in an observational study that included 76 patients with nonpulmonary infections due to <em>M. fortuitum</em>, 68 patients (90 percent) were successfully treated [<a href="#rid18">18</a>]. Most patients had skin and soft tissue infections, but 15 had osteomyelitis. The same study included 47 patients with nonpulmonary infections due to <em>M. chelonae</em> or <em>M. abscessus</em>, of whom 34 patients (72 percent) were successfully treated. Only seven of these patients had osteomyelitis.</p><p>Good outcomes have been described with vertebral osteomyelitis. In one review, 81 percent of patients without HIV (45 of 47) and 90 percent of patients with HIV (9 of 10) recovered, improved, or achieved a pain-free state [<a href="#rid17">17,76</a>]. Four patients died during follow-up, but the deaths were not due to NTM. Outcomes were not analyzed by species. In an earlier review of 38 patients with vertebral osteomyelitis due to <em>M. abscessus</em>, full recovery occurred in 79 percent and partial recovery in 11 percent [<a href="#rid94">94</a>]. </p><p class="headingAnchor" id="H2770258819"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113062.html" rel="external">"Society guideline links: Nontuberculous mycobacteria"</a>.)</p><p class="headingAnchor" id="H542359714"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multidisciplinary approach</strong> – Osteomyelitis caused by nontuberculous mycobacteria (NTM) requires combination antimycobacterial therapy, often in conjunction with surgery. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination antimycobacterial therapy</strong> – We suggest combination antimycobacterial therapy for patients with osteomyelitis due to NTM (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice of the antimycobacterial regimen should be chosen based upon the usual regimens given for the specific NTM species isolated and, for certain species, on the results of in vitro susceptibility testing. Concomitant immunosuppression should be minimized whenever possible. </p><p></p><p class="bulletIndent1">In vitro susceptibility testing is recommended for the majority of NTM species isolated from the lesions of patients with osteomyelitis. Specific testing and regimen selection for each NTM species are discussed above. (See <a class="local">'Antimycobacterial therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical intervention</strong> – For patients with localized osteomyelitis due to <em>Mycobacterium avium</em> complex, we suggest a combination of excisional surgery or surgical debridement and antimycobacterial therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We also suggest surgical debridement (in addition to antimycobacterial therapy) for patients with osteomyelitis due to other NTM species when there is extensive local involvement, an abscess, vertebral osteomyelitis, involvement of the closed spaces of the hand, or when antimycobacterial therapy alone is poorly tolerated or does not result in clinical improvement (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Surgery is indicated for NTM species that are difficult to treat medically, such as <em>Mycobacterium chelonae</em> and <em>Mycobacterium abscessus</em>. (See <a class="local">'Surgery'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – The duration of antimycobacterial therapy depends upon several factors, including the response to treatment, the causative species, and the immune status of the patient. Antimycobacterial therapy is typically continued for a minimum of 6 months and is sometimes given for 12 months or longer. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonresponse to therapy</strong> – If the patient does not respond to antimycobacterial therapy, then surgical debridement, repeating cultures and performing (or repeating) susceptibility testing, and additional antimycobacterial therapy, such as the addition of a parenteral agent, are the next steps. (See <a class="local">'Managing poor treatment responses'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</a></li><li><a class="nounderline abstract_t">Kurz SG, Zha BS, Herman DD, et al. Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease. Ann Am Thorac Soc 2020; 17:1033.</a></li><li class="breakAll">Clinical and Laboratory Standards Institute. Susceptibility testing of mycobacteria, nocardia spp, and other aerobic actinomyces. 3rd ed. M24. Clinical and Laboratory Standards Institute. Wayne, PA 2018.</li><li class="breakAll">Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, nocardia spp, and other aerobic actinomyces. 1st ed. M62. Clinical and Laboratory Standards Institute. Wayne, PA 2018.</li><li><a class="nounderline abstract_t">Tanagho A, Hatab S, Hawkins A. Atypical Osteomyelitis Caused by Mycobacterium chelonae in a Nonimmunocompromised Patient: A Case Report. JBJS Case Connect 2015; 5:e17.</a></li><li><a class="nounderline abstract_t">Goldstein N, St Clair JB, Kasperbauer SH, et al. Nontuberculous Mycobacterial Musculoskeletal Infection Cases from a Tertiary Referral Center, Colorado, USA. Emerg Infect Dis 2019; 25:1075.</a></li><li><a class="nounderline abstract_t">Cho EH, Huh HJ, Song DJ, et al. Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens. Diagn Microbiol Infect Dis 2019; 93:107.</a></li><li><a class="nounderline abstract_t">Hatakeyama S, Ohama Y, Okazaki M, et al. Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan. BMC Infect Dis 2017; 17:197.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Killingley J, Vasireddy S, et al. In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest. J Clin Microbiol 2016; 54:1586.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria. Antimicrob Agents Chemother 2021; 65.</a></li><li><a class="nounderline abstract_t">Kim DH, Jhun BW, Moon SM, et al. In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Nash KA, Zhang Y, Brown-Elliott BA, Wallace RJ Jr. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum. J Antimicrob Chemother 2005; 55:170.</a></li><li><a class="nounderline abstract_t">Stone MS, Wallace RJ Jr, Swenson JM, et al. Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics. Antimicrob Agents Chemother 1983; 24:486.</a></li><li><a class="nounderline abstract_t">Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.</a></li><li><a class="nounderline abstract_t">Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG. Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities. J Infect Dis 1985; 152:500.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.</a></li><li><a class="nounderline abstract_t">Hunkins JJ, de-Moura VC, Eddy JJ, et al. In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States. Diagn Microbiol Infect Dis 2023; 105:115882.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria. Antimicrob Agents Chemother 2022; 66:e0068922.</a></li><li><a class="nounderline abstract_t">Adékambi T, Reynaud-Gaubert M, Greub G, et al. Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia. J Clin Microbiol 2004; 42:5493.</a></li><li><a class="nounderline abstract_t">Adékambi T, Berger P, Raoult D, Drancourt M. rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov. Int J Syst Evol Microbiol 2006; 56:133.</a></li><li><a class="nounderline abstract_t">Leao SC, Tortoli E, Euzéby JP, Garcia MJ. Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus. Int J Syst Evol Microbiol 2011; 61:2311.</a></li><li><a class="nounderline abstract_t">Tortoli E, Kohl TA, Brown-Elliott BA, et al. Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov. Int J Syst Evol Microbiol 2016; 66:4471.</a></li><li><a class="nounderline abstract_t">Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Vasireddy S, Vasireddy R, et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol 2015; 53:1211.</a></li><li><a class="nounderline abstract_t">Lefebvre AL, Dubée V, Cortes M, et al. Bactericidal and intracellular activity of β-lactams against Mycobacterium abscessus. J Antimicrob Chemother 2016; 71:1556.</a></li><li><a class="nounderline abstract_t">Gumbo T, Cirrincione K, Srivastava S. Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill. J Antimicrob Chemother 2020; 75:1212.</a></li><li><a class="nounderline abstract_t">Wallace RJ Jr, Dukart G, Brown-Elliott BA, et al. Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections. J Antimicrob Chemother 2014; 69:1945.</a></li><li><a class="nounderline abstract_t">Kwon YS, Levin A, Kasperbauer SH, et al. Efficacy and safety of tigecycline for Mycobacterium abscessus disease. Respir Med 2019; 158:89.</a></li><li><a class="nounderline abstract_t">Yang B, Jhun BW, Moon SM, et al. Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Ferro BE, Meletiadis J, Wattenberg M, et al. Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin. Antimicrob Agents Chemother 2016; 60:1097.</a></li><li><a class="nounderline abstract_t">Martiniano SL, Wagner BD, Levin A, et al. Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection. Chest 2017; 152:800.</a></li><li><a class="nounderline abstract_t">McGuffin SA, Pottinger PS, Harnisch JP. Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche. Open Forum Infect Dis 2017; 4:ofx147.</a></li><li><a class="nounderline abstract_t">Choi GE, Shin SJ, Won CJ, et al. Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. Am J Respir Crit Care Med 2012; 186:917.</a></li><li><a class="nounderline abstract_t">Obregón-Henao A, Arnett KA, Henao-Tamayo M, et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother 2015; 59:6904.</a></li><li><a class="nounderline abstract_t">Philley JV, Wallace RJ Jr, Benwill JL, et al. Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease. Chest 2015; 148:499.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Wallace RJ Jr. In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria. J Clin Microbiol 2017; 55:1747.</a></li><li><a class="nounderline abstract_t">Compain F, Soroka D, Heym B, et al. In vitro activity of tedizolid against the Mycobacterium abscessus complex. Diagn Microbiol Infect Dis 2018; 90:186.</a></li><li><a class="nounderline abstract_t">Ruth MM, Koeken VACM, Pennings LJ, et al. Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease? J Antimicrob Chemother 2020; 75:609.</a></li><li><a class="nounderline abstract_t">Le Run E, Arthur M, Mainardi JL. In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Tang YW, Cheng B, Yeoh SF, et al. Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study. Front Microbiol 2018; 9:2095.</a></li><li><a class="nounderline abstract_t">Morrisette T, Alosaimy S, Philley JV, et al. Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections. Open Forum Infect Dis 2021; 8:ofab002.</a></li><li><a class="nounderline abstract_t">Mingora CM, Bullington W, Faasuamalie PE, et al. Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections. Open Forum Infect Dis 2023; 10:ofad335.</a></li><li><a class="nounderline abstract_t">Karlowsky JA, Steenbergen J, Zhanel GG. Microbiology and Preclinical Review of Omadacycline. Clin Infect Dis 2019; 69:S6.</a></li><li><a class="nounderline abstract_t">Bax HI, de Vogel CP, Mouton JW, de Steenwinkel JEM. Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus. J Antimicrob Chemother 2019; 74:2930.</a></li><li><a class="nounderline abstract_t">Kaushik A, Ammerman NC, Martins O, et al. In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Shoen C, Benaroch D, Sklaney M, Cynamon M. In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Rizzo AR, Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use. BMC Infect Dis 2022; 22:874.</a></li><li><a class="nounderline abstract_t">Story-Roller E, Maggioncalda EC, Cohen KA, Lamichhane G. Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities. Front Microbiol 2018; 9:2273.</a></li><li><a class="nounderline abstract_t">Kaushik A, Ammerman NC, Lee J, et al. In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Dubée V, Soroka D, Cortes M, et al. Impact of β-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother 2015; 59:2938.</a></li><li><a class="nounderline abstract_t">Pandey R, Chen L, Manca C, et al. Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro. mBio 2019; 10.</a></li><li><a class="nounderline abstract_t">Jarand J, Levin A, Zhang L, et al. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis 2011; 52:565.</a></li><li><a class="nounderline abstract_t">Jeon K, Kwon OJ, Lee NY, et al. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009; 180:896.</a></li><li><a class="nounderline abstract_t">Jeong SH, Kim SY, Huh HJ, et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. Int J Infect Dis 2017; 60:49.</a></li><li><a class="nounderline abstract_t">Bernard L, Vincent V, Lortholary O, et al. Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review. Clin Infect Dis 1999; 29:1455.</a></li><li><a class="nounderline abstract_t">Yano T, Okuda S, Kato K, et al. Mycobacterium kansasii osteomyelitis in a patient with AIDS on highly active antiretroviral therapy. Intern Med 2004; 43:1084.</a></li><li><a class="nounderline abstract_t">Tsai CW, Wang JT, Tsai CC, Yeh KH. Disseminated Mycobacterium kansasii infection in an HIV-negative patient presenting with mimicking multiple bone metastases. Diagn Microbiol Infect Dis 2006; 54:211.</a></li><li><a class="nounderline abstract_t">Williams B, Neth O, Shingadia D, et al. Mycobacterium kansasii causing septic arthritis and osteomyelitis in a child. Pediatr Infect Dis J 2010; 29:88.</a></li><li><a class="nounderline abstract_t">Griffith DE, Brown-Elliott BA, Wallace RJ Jr. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin Infect Dis 2003; 37:1178.</a></li><li><a class="nounderline abstract_t">Shitrit D, Baum GL, Priess R, et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest 2006; 129:771.</a></li><li><a class="nounderline abstract_t">Pezzia W, Raleigh JW, Bailey MC, et al. Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. Rev Infect Dis 1981; 3:1035.</a></li><li><a class="nounderline abstract_t">Ahn CH, Lowell JR, Ahn SS, et al. Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. Rev Infect Dis 1981; 3:1028.</a></li><li><a class="nounderline abstract_t">Ahn CH, Lowell JR, Ahn SS, et al. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am Rev Respir Dis 1983; 128:1048.</a></li><li><a class="nounderline abstract_t">Banks J, Hunter AM, Campbell IA, et al. Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response. Thorax 1983; 38:271.</a></li><li><a class="nounderline abstract_t">Elsayed S, Read R. Mycobacterium haemophilum osteomyelitis: case report and review of the literature. BMC Infect Dis 2006; 6:70.</a></li><li><a class="nounderline abstract_t">Shah MK, Sebti A, Kiehn TE, et al. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 2001; 33:330.</a></li><li><a class="nounderline abstract_t">Bernard EM, Edwards FF, Kiehn TE, et al. Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum. Antimicrob Agents Chemother 1993; 37:2323.</a></li><li><a class="nounderline abstract_t">McBride ME, Rudolph AH, Tschen JA, et al. Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol 1991; 127:276.</a></li><li><a class="nounderline abstract_t">Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162:1746.</a></li><li><a class="nounderline abstract_t">Nguyen HH, Fadul N, Ashraf MS, Siraj DS. Osteomyelitis Infection of Mycobacterium marinum: A Case Report and Literature Review. Case Rep Infect Dis 2015; 2015:905920.</a></li><li><a class="nounderline abstract_t">Petitjean G, Fluckiger U, Schären S, Laifer G. Vertebral osteomyelitis caused by non-tuberculous mycobacteria. Clin Microbiol Infect 2004; 10:951.</a></li><li><a class="nounderline abstract_t">Kim CJ, Kim UJ, Kim HB, et al. Vertebral osteomyelitis caused by non-tuberculous mycobacteria: Predisposing conditions and clinical characteristics of six cases and a review of 63 cases in the literature. Infect Dis (Lond) 2016; 48:509.</a></li><li><a class="nounderline abstract_t">Yeh CF, Tu TY, Wang MC, et al. Emergence of Refractory Otomastoiditis Due to Nontuberculous Mycobacteria: Institutional Experience and Review of the Literature. Clin Infect Dis 2016; 62:739.</a></li><li><a class="nounderline abstract_t">Marr MA, Algozzine GJ. Use of bone cement containing tobramycin sulfate. Clin Pharm 1983; 2:401.</a></li><li><a class="nounderline abstract_t">Klekamp J, Dawson JM, Haas DW, et al. The use of vancomycin and tobramycin in acrylic bone cement: biomechanical effects and elution kinetics for use in joint arthroplasty. J Arthroplasty 1999; 14:339.</a></li><li><a class="nounderline abstract_t">Hanssen AD, Spangehl MJ. Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements. Clin Orthop Relat Res 2004; :79.</a></li><li><a class="nounderline abstract_t">González Della Valle A, Bostrom M, Brause B, et al. Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement. Acta Orthop Scand 2001; 72:237.</a></li><li><a class="nounderline abstract_t">Scott CP, Higham PA, Dumbleton JH. Effectiveness of bone cement containing tobramycin. An in vitro susceptibility study of 99 organisms found in infected joint arthroplasty. J Bone Joint Surg Br 1999; 81:440.</a></li><li><a class="nounderline abstract_t">Nelson CL, Griffin FM, Harrison BH, Cooper RE. In vitro elution characteristics of commercially and noncommercially prepared antibiotic PMMA beads. Clin Orthop Relat Res 1992; :303.</a></li><li><a class="nounderline abstract_t">Adams K, Couch L, Cierny G, et al. In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads. Clin Orthop Relat Res 1992; :244.</a></li><li><a class="nounderline abstract_t">Seeley SK, Seeley JV, Telehowski P, et al. Volume and surface area study of tobramycin-polymethylmethacrylate beads. Clin Orthop Relat Res 2004; :298.</a></li><li><a class="nounderline abstract_t">Evans RP. Successful treatment of total hip and knee infection with articulating antibiotic components: a modified treatment method. Clin Orthop Relat Res 2004; :37.</a></li><li><a class="nounderline abstract_t">Greene N, Holtom PD, Warren CA, et al. In vitro elution of tobramycin and vancomycin polymethylmethacrylate beads and spacers from Simplex and Palacos. Am J Orthop (Belle Mead NJ) 1998; 27:201.</a></li><li><a class="nounderline abstract_t">Kuechle DK, Landon GC, Musher DM, Noble PC. Elution of vancomycin, daptomycin, and amikacin from acrylic bone cement. Clin Orthop Relat Res 1991; :302.</a></li><li><a class="nounderline abstract_t">Masri BA, Duncan CP, Jewesson P, et al. Streptomycin-loaded bone cement in the treatment of tuberculous osteomyelitis: an adjunct to conventional therapy. Can J Surg 1995; 38:64.</a></li><li><a class="nounderline abstract_t">Kerens B, Gans EH, Pilot P, et al. [Atypical tuberculous osteomyelitis of the humeral shaft caused by Mycobacterium avium]. Ned Tijdschr Geneeskd 2006; 150:1728.</a></li><li><a class="nounderline abstract_t">Pring M, Eckhoff DG. Mycobacterium chelonae infection following a total knee arthroplasty. J Arthroplasty 1996; 11:115.</a></li><li><a class="nounderline abstract_t">Curtis JM, Sternhagen V, Batts D. Acute renal failure after placement of tobramycin-impregnated bone cement in an infected total knee arthroplasty. Pharmacotherapy 2005; 25:876.</a></li><li><a class="nounderline abstract_t">Patrick BN, Rivey MP, Allington DR. Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty. Ann Pharmacother 2006; 40:2037.</a></li><li><a class="nounderline abstract_t">Garcia DC, Sandoval-Sus J, Razzaq K, Young L. Vertebral osteomyelitis caused by Mycobacterium abscessus. BMJ Case Rep 2013; 2013.</a></li></ol></div><div id="topicVersionRevision">Topic 13995 Version 18.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17277290" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870060" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870060" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32870060" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Summary for Clinicians: 2020 Clinical Practice Guideline Summary for the Treatment of Nontuberculous Mycobacterial Pulmonary Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29252450" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Atypical Osteomyelitis Caused by Mycobacterium chelonae in a Nonimmunocompromised Patient: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31107224" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nontuberculous Mycobacterial Musculoskeletal Infection Cases from a Tertiary Referral Center, Colorado, USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30236529" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Drug susceptibility patterns of Mycobacterium abscessus and Mycobacterium massiliense isolated from respiratory specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270102" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27053677" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : In Vitro Comparison of Ertapenem, Meropenem, and Imipenem against Isolates of Rapidly Growing Mycobacteria and Nocardia by Use of Broth Microdilution and Etest.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30509936" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33288634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In Vitro Susceptibility Testing of Omadacycline against Nontuberculous Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182533" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : In Vitro Activity of Bedaquiline and Delamanid against Nontuberculous Mycobacteria, Including Macrolide-Resistant Clinical Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15590712" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6651277" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4083863" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1317144" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2069387" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3875667" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Treatment of nonpulmonary infections due to Mycobacterium fortuitum and Mycobacterium chelonei on the basis of in vitro susceptibilities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1386098" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181357" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Activities of linezolid against rapidly growing mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36610383" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35943269" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : In Vitro Susceptibility Testing of Eravacycline against Nontuberculous Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15583272" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Amoebal coculture of "Mycobacterium massiliense" sp. nov. from the sputum of a patient with hemoptoic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16403878" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : rpoB gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of Mycobacterium bolletii sp. nov., Mycobacterium phocaicum sp. nov. and Mycobacterium aubagnense sp. nov.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21037035" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Proposal that Mycobacterium massiliense and Mycobacterium bolletii be united and reclassified as Mycobacterium abscessus subsp. bolletii comb. nov., designation of Mycobacterium abscessus subsp. abscessus subsp. nov. and emended description of Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27499141" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19171799" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25653399" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26929268" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Bactericidal and intracellular activity ofβ-lactams against Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016429" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Repurposing drugs for treatment of Mycobacterium abscessus: a view to a kill.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24633206" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31622813" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Efficacy and safety of tigecycline for Mycobacterium abscessus disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28348153" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Clofazimine-Containing Regimen for the Treatment of Mycobacterium abscessus Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26643335" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28483608" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30202770" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clofazimine in Nontuberculous Mycobacterial Infections: A Growing Niche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22878281" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26303795" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25675393" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28330892" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : In Vitro Susceptibility Testing of Tedizolid against Nontuberculous Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29217419" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : In vitro activity of tedizolid against the Mycobacterium abscessus complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31886864" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30745387" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : In Vitro and Intracellular Activity of Imipenem Combined with Tedizolid, Rifabutin, and Avibactam against Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30245674" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Tedizolid Activity Against Clinical Mycobacterium abscessus Complex Isolates-An in vitro Characterization Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33628856" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37476076" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31367743" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Microbiology and Preclinical Review of Omadacycline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31236595" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30962331" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : In Vitro Activity of New Tetracycline Analogs Omadacycline and Eravacycline against Drug-Resistant Clinical Isolates of Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30858221" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : In Vitro Activities of Omadacycline against Rapidly Growing Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36419143" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Omadacycline for management of Mycobacterium abscessus infections: a review of its effectiveness, place in therapy, and considerations for use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30319581" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Mycobacterium abscessus andβ-Lactams: Emerging Insights and Potential Opportunities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30642943" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : In Vitro Activity of the Newβ-Lactamase Inhibitors Relebactam and Vaborbactam in Combination withβ-Lactams against Mycobacterium abscessus Complex Clinical Isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25733512" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Impact ofβ-lactamase inhibition on the activity of ceftaroline against Mycobacterium tuberculosis and Mycobacterium abscessus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30755518" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Dualβ-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21292659" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661243" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28522316" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585795" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mycobacterium kansasii septic arthritis: French retrospective study of 5 years and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609709" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Mycobacterium kansasii osteomyelitis in a patient with AIDS on highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16423487" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Disseminated Mycobacterium kansasii infection in an HIV-negative patient presenting with mimicking multiple bone metastases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19884872" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Mycobacterium kansasii causing septic arthritis and osteomyelitis in a child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557961" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16537880" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7339801" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7339800" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6650978" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6867979" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pulmonary infection with Mycobacterium kansasii in Wales, 1970-9: review of treatment and response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606464" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Mycobacterium haemophilum osteomyelitis: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438898" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Mycobacterium haemophilum in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8285613" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Activities of antimicrobial agents against clinical isolates of Mycobacterium haemophilum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991007" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12153378" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25664190" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Osteomyelitis Infection of Mycobacterium marinum: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15521995" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Vertebral osteomyelitis caused by non-tuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27002256" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Vertebral osteomyelitis caused by non-tuberculous mycobacteria: Predisposing conditions and clinical characteristics of six cases and a review of 63 cases in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26689957" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Emergence of Refractory Otomastoiditis Due to Nontuberculous Mycobacteria: Institutional Experience and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6627868" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Use of bone cement containing tobramycin sulfate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10220189" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The use of vancomycin and tobramycin in acrylic bone cement: biomechanical effects and elution kinetics for use in joint arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15552141" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11480597" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Effective bactericidal activity of tobramycin and vancomycin eluted from acrylic bone cement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10872362" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Effectiveness of bone cement containing tobramycin. An in vitro susceptibility study of 99 organisms found in infected joint arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1395310" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : In vitro elution characteristics of commercially and noncommercially prepared antibiotic PMMA beads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1563160" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : In vitro and in vivo evaluation of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylate beads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15057112" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Volume and surface area study of tobramycin-polymethylmethacrylate beads.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15552134" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Successful treatment of total hip and knee infection with articulating antibiotic components: a modified treatment method.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9544361" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : In vitro elution of tobramycin and vancomycin polymethylmethacrylate beads and spacers from Simplex and Palacos.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1705191" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Elution of vancomycin, daptomycin, and amikacin from acrylic bone cement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7882212" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Streptomycin-loaded bone cement in the treatment of tuberculous osteomyelitis: an adjunct to conventional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16924946" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : [Atypical tuberculous osteomyelitis of the humeral shaft caused by Mycobacterium avium].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8676110" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mycobacterium chelonae infection following a total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15927906" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Acute renal failure after placement of tobramycin-impregnated bone cement in an infected total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17032907" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Acute renal failure associated with vancomycin- and tobramycin-laden cement in total hip arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23925676" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Vertebral osteomyelitis caused by Mycobacterium abscessus.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
